Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

M. Herold, E. Hoster, A. Janssens, H. McCarthy, A. Tedeschi, C. Pocock, A. Rosta, M. Trněný, TG. Nielsen, A. Knapp, W. Hiddemann, R. Marcus

. 2022 ; 6 (3) : e699. [pub] 20220224

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22009932

The aim of this study was to explore the efficacy and safety of obinutuzumab (G)- versus rituximab (R)-chemotherapy in a subgroup of patients with previously untreated marginal zone lymphoma (MZL) in the phase III GALLIUM trial (NCT01332968). Patients had stage III/IV (or stage II with bulky disease), splenic, nodal, or extranodal MZL requiring treatment. Patients were randomized 1:1 to receive G- or R-chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone; cyclophosphamide, vincristine, and prednisone; or bendamustine, allocated at patient level). Patients with complete/partial response at the end of induction (EOI) received G/R maintenance. Investigator-assessed progression-free survival (PFS), other time-to-event endpoints, response, and safety were assessed. Overall, 195 patients with MZL were included in this analysis: G-chemotherapy (n = 99), R-chemotherapy (n = 96). Median observation time: 59.3 months. No meaningful difference was observed between arms for PFS (4-y PFS rates: G-chemotherapy, 72.6%; R-chemotherapy, 64.1%), other time-to-event endpoints, or EOI response rates (by computed tomography [CT; G-chemotherapy, 81.8%; R-chemotherapy, 81.3%] and positron emission tomography CT [G-chemotherapy, 79.2%; R-chemotherapy, 87.5%]). All patients experienced ≥1 adverse event (AE). G-chemotherapy was associated with a higher incidence of grade 3-5 (86.1% versus 77.4%), grade 5 (14.9% versus 9.7%), and serious (66.3% versus 51.6%) AEs versus R-chemotherapy. Both arms had a higher incidence of grade 3-5 and serious AEs than patients with follicular lymphoma (GALLIUM), with G-chemotherapy being less tolerable than R-chemotherapy. Based on the observed tolerability of G-chemotherapy versus R-chemotherapy, and the comparable efficacy of G-chemotherapy and R-chemotherapy in this analysis, G-chemotherapy cannot be recommended as first-line treatment for MZL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22009932
003      
CZ-PrNML
005      
20220425131628.0
007      
ta
008      
220420s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/HS9.0000000000000699 $2 doi
035    __
$a (PubMed)35233508
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Herold, Michael $u Helios Klinikum Erfurt, Germany
245    10
$a Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial / $c M. Herold, E. Hoster, A. Janssens, H. McCarthy, A. Tedeschi, C. Pocock, A. Rosta, M. Trněný, TG. Nielsen, A. Knapp, W. Hiddemann, R. Marcus
520    9_
$a The aim of this study was to explore the efficacy and safety of obinutuzumab (G)- versus rituximab (R)-chemotherapy in a subgroup of patients with previously untreated marginal zone lymphoma (MZL) in the phase III GALLIUM trial (NCT01332968). Patients had stage III/IV (or stage II with bulky disease), splenic, nodal, or extranodal MZL requiring treatment. Patients were randomized 1:1 to receive G- or R-chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone; cyclophosphamide, vincristine, and prednisone; or bendamustine, allocated at patient level). Patients with complete/partial response at the end of induction (EOI) received G/R maintenance. Investigator-assessed progression-free survival (PFS), other time-to-event endpoints, response, and safety were assessed. Overall, 195 patients with MZL were included in this analysis: G-chemotherapy (n = 99), R-chemotherapy (n = 96). Median observation time: 59.3 months. No meaningful difference was observed between arms for PFS (4-y PFS rates: G-chemotherapy, 72.6%; R-chemotherapy, 64.1%), other time-to-event endpoints, or EOI response rates (by computed tomography [CT; G-chemotherapy, 81.8%; R-chemotherapy, 81.3%] and positron emission tomography CT [G-chemotherapy, 79.2%; R-chemotherapy, 87.5%]). All patients experienced ≥1 adverse event (AE). G-chemotherapy was associated with a higher incidence of grade 3-5 (86.1% versus 77.4%), grade 5 (14.9% versus 9.7%), and serious (66.3% versus 51.6%) AEs versus R-chemotherapy. Both arms had a higher incidence of grade 3-5 and serious AEs than patients with follicular lymphoma (GALLIUM), with G-chemotherapy being less tolerable than R-chemotherapy. Based on the observed tolerability of G-chemotherapy versus R-chemotherapy, and the comparable efficacy of G-chemotherapy and R-chemotherapy in this analysis, G-chemotherapy cannot be recommended as first-line treatment for MZL.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hoster, Eva $u Department of Medicine III, Ludwig-Maximilians-University Hospital Munich, Germany $u Institute of Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-University, Munich, Germany
700    1_
$a Janssens, Ann $u Department of Hematology, Universitaire Ziekenhuizen Leuven, Belgium
700    1_
$a McCarthy, Helen $u Department of Haematology, Royal Bournemouth General Hospital, Bournemouth, United Kingdom
700    1_
$a Tedeschi, Alessandra $u Department of Hematology, Niguarda Hospital, Milan, Italy
700    1_
$a Pocock, Chris $u East Kent Hospitals NHS Trust, Canterbury, United Kingdom
700    1_
$a Rosta, Andras $u Department of Haematology, Országos Onkológiai Intézet, Budapest, Hungary
700    1_
$a Trněný, Marek $u 1 Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Nielsen, Tina G $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Knapp, Andrea $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Hiddemann, Wolfgang $u Department of Medicine III, Ludwig-Maximilians-University Hospital Munich, Germany
700    1_
$a Marcus, Robert $u HCA Healthcare, London, United Kingdom
773    0_
$w MED00201259 $t HemaSphere $x 2572-9241 $g Roč. 6, č. 3 (2022), s. e699
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35233508 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20220425131626 $b ABA008
999    __
$a ind $b bmc $g 1784441 $s 1161130
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 6 $c 3 $d e699 $e 20220224 $i 2572-9241 $m HemaSphere $n Hemasphere $x MED00201259
LZP    __
$a Pubmed-20220420

Najít záznam

Citační ukazatele

Možnosti archivace